Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes.

PubWeight™: 0.89‹?›

🔗 View Article (PMC 3679212)

Published in Hum Vaccin on January 01, 2011

Authors

Benjamin G Keselowsky1, Chang Qing Xia, Michael Clare-Salzler

Author Affiliations

1: J Crayton Pruitt Family Department of Biomedical Engineering, College of Medicine; University of Florida, Gainesville, FL, USA. bgk@ufl.edu

Associated clinical trials:

Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study | NCT00445913

Articles citing this

Microparticle surface modifications targeting dendritic cells for non-activating applications. Biomaterials (2012) 0.99

Dendritic cell subsets in type 1 diabetes: friend or foe? Front Immunol (2013) 0.88

It's time to bring dendritic cell therapy to type 1 diabetes. Diabetes (2014) 0.85

Integrin-directed modulation of macrophage responses to biomaterials. Biomaterials (2014) 0.83

Combinatorial delivery of immunosuppressive factors to dendritic cells using dual-sized microspheres. J Mater Chem B Mater Biol Med (2014) 0.82

Combinatorial co-encapsulation of hydrophobic molecules in poly(lactide-co-glycolide) microparticles. Biomaterials (2013) 0.80

Materials that harness and modulate the immune system. MRS Bull (2014) 0.80

A combination dual-sized microparticle system modulates dendritic cells and prevents type 1 diabetes in prediabetic NOD mice. Clin Immunol (2015) 0.79

A combination hydrogel microparticle-based vaccine prevents type 1 diabetes in non-obese diabetic mice. Sci Rep (2015) 0.78

Micro and Nano Material Carriers for Immunomodulation. Am J Transplant (2016) 0.75

In vivo delivery of nucleic acid-formulated microparticles as a potential tolerogenic vaccine for type 1 diabetes. Rev Diabet Stud (2012) 0.75

A cell-based microarray to investigate combinatorial effects of microparticle-encapsulated adjuvants on dendritic cell activation. J Mater Chem B Mater Biol Med (2015) 0.75

An introduction to biomaterial-based strategies for curbing autoimmunity. Exp Biol Med (Maywood) (2016) 0.75

Articles cited by this

(truncated to the top 100)

Immunobiology of dendritic cells. Annu Rev Immunol (2000) 23.65

Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol (2005) 13.90

Tolerogenic dendritic cells. Annu Rev Immunol (2001) 13.77

Taking dendritic cells into medicine. Nature (2007) 11.82

Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med (2001) 9.70

Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med (2002) 6.56

Dendritic cells: features and functions. Immunol Rev (1980) 6.34

Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet (2001) 6.14

Immune inhibitory receptors. Science (2000) 6.05

Fcgamma receptors: old friends and new family members. Immunity (2006) 5.60

Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature (2006) 5.54

The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature (1995) 5.13

In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med (2004) 5.07

Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol (1997) 5.06

Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol (2009) 4.90

Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med (2003) 4.64

DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10

Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol (2002) 3.91

Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol (2007) 3.75

The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J Immunol (2002) 3.48

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol (2007) 3.42

CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol (2007) 3.06

T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science (1994) 3.00

PD-1 and its ligands in T-cell immunity. Curr Opin Immunol (2007) 2.86

New challenges in biomaterials. Science (1994) 2.85

A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. J Exp Med (2007) 2.82

Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res (1991) 2.70

CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J Immunol (2008) 2.69

Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med (2002) 2.54

Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med (2006) 2.53

Phagocytosis and antigen presentation in dendritic cells. Immunol Rev (2007) 2.49

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol (2004) 2.48

Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity (2010) 2.44

Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med (2006) 2.43

Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol (2004) 2.33

Dendritic cells in vivo: a key target for a new vaccine science. Immunity (2008) 2.31

Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J Exp Med (1995) 2.24

Materials engineering for immunomodulation. Nature (2009) 2.18

Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther (2007) 2.17

The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18). J Exp Med (2001) 2.12

In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release (2006) 2.05

Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat Mater (2004) 2.03

Infection-mimicking materials to program dendritic cells in situ. Nat Mater (2009) 2.00

Antigenic targeting of the human mannose receptor induces tumor immunity. J Immunol (2007) 1.93

Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology (2006) 1.92

Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood (2003) 1.91

Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev (2005) 1.89

Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol (2006) 1.85

Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines (2007) 1.76

Interaction of nanoparticles with cells. Biomacromolecules (2009) 1.73

Dcir deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells. Nat Med (2008) 1.73

Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol (2002) 1.66

Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev (2003) 1.61

Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood (2005) 1.57

'The honeymoon phase' in children with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatr Diabetes (2006) 1.56

CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci U S A (1999) 1.55

Toward a cure for type 1 diabetes mellitus: diabetes-suppressive dendritic cells and beyond. Pediatr Diabetes (2008) 1.50

PEG-SS-PPS: reduction-sensitive disulfide block copolymer vesicles for intracellular drug delivery. Biomacromolecules (2007) 1.49

Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. Proc Natl Acad Sci U S A (2008) 1.49

Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine (2004) 1.44

Cyclosporin therapy for prevention and cure of IDDM. Epidemiological perspective of benefits and risks. Diabetes Care (1990) 1.43

Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J Immunol (1996) 1.38

Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity. Eur J Immunol (2007) 1.33

Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release (2010) 1.32

Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol (2010) 1.29

On the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes. Diabetes (2005) 1.29

TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine (2008) 1.26

Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol (1999) 1.26

Development of dendritic cell-based immunotherapy for autoimmunity. Int Rev Immunol (2010) 1.24

In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc Natl Acad Sci U S A (2005) 1.22

Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Deliv Rev (2005) 1.22

Type 1 diabetes mellitus: etiology, presentation, and management. Pediatr Clin North Am (2005) 1.21

Injectable polymer microspheres enhance immunogenicity of a contraceptive peptide vaccine. Vaccine (2006) 1.18

Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine (2008) 1.17

Lymphatic drainage function and its immunological implications: from dendritic cell homing to vaccine design. Semin Immunol (2008) 1.17

Delivery of rapamycin to dendritic cells using degradable microparticles. J Control Release (2008) 1.17

Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J Immunol (2004) 1.16

Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res (2002) 1.16

The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity. J Immunol (2006) 1.16

PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev (2005) 1.15

Immunity induced after a feed of antigen during early life: oral tolerance v. sensitisation. Proc Nutr Soc (2001) 1.14

Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J Immunol (2004) 1.12

Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum Immunol (2009) 1.12

Polyketal microparticles: a new delivery vehicle for superoxide dismutase. Bioconjug Chem (2007) 1.12

Modulation of dendritic cells using granulocyte-macrophage colony-stimulating factor (GM-CSF) delays type 1 diabetes by enhancing CD4+CD25+ regulatory T cell function. Clin Immunol (2009) 1.11

Directed cell migration via chemoattractants released from degradable microspheres. Biomaterials (2005) 1.11

Interleukin-7 is a survival factor for CD4+ CD25+ T-cells and is expressed by diabetes-suppressive dendritic cells. Diabetes (2006) 1.10

"Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells. J Immunother (2007) 1.09

Induction of peripheral CD4+ T-cell tolerance and CD8+ T-cell cross-tolerance by dendritic cells. Eur J Immunol (2009) 1.09

Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation. Bioconjug Chem (2009) 1.06

In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells. Biomaterials (2009) 1.05

Adhesive substrate-modulation of adaptive immune responses. Biomaterials (2008) 1.05

Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine (2005) 1.05

The stimulation of CD8+ T cells by dendritic cells pulsed with polyketal microparticles containing ion-paired protein antigen and poly(inosinic acid)-poly(cytidylic acid). Biomaterials (2008) 1.03

Targeting antigens to dendritic cells in vivo. Immunobiology (2006) 1.02

Effect of poly(lactic-co-glycolic acid) contact on maturation of murine bone marrow-derived dendritic cells. J Biomed Mater Res A (2007) 1.02

Injectable dendritic cell-carrying alginate gels for immunization and immunotherapy. Biomaterials (2008) 1.02

Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur J Immunol (2000) 1.01

A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes (2008) 1.01

Harnessing dendritic cells to generate cancer vaccines. Ann N Y Acad Sci (2009) 1.01

Articles by these authors

MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med (2007) 5.48

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39

Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA (2007) 2.04

No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes (2007) 1.99

Characterization of the systemic loss of dendritic cells in murine lymph nodes during polymicrobial sepsis. J Immunol (2004) 1.36

Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes (2007) 1.22

Reduced serum vitamin D-binding protein levels are associated with type 1 diabetes. Diabetes (2011) 1.10

Eicosanoid imbalance in the NOD mouse is related to a dysregulation in soluble epoxide hydrolase and 15-PGDH expression. Ann N Y Acad Sci (2006) 0.91

Erythrocyte membrane omega-3 fatty acid levels and omega-3 fatty acid intake are not associated with conversion to type 1 diabetes in children with islet autoimmunity: the Diabetes Autoimmunity Study in the Young (DAISY). Pediatr Diabetes (2011) 0.90

Rabbit polyclonal mouse antithymocyte globulin administration alters dendritic cell profile and function in NOD mice to suppress diabetogenic responses. J Immunol (2009) 0.89

Adhesive substrates modulate the activation and stimulatory capacity of non-obese diabetic mouse-derived dendritic cells. Acta Biomater (2010) 0.88

Truncated pStat5B is associated with the Idd4 locus in NOD mice. Biochem Biophys Res Commun (2007) 0.87

Erythrocyte membrane fatty acid content in infants consuming formulas supplemented with docosahexaenoic acid (DHA) and arachidonic acid (ARA): an observational study. Matern Child Nutr (2010) 0.87

Novel leptin receptor mutation in NOD/LtJ mice suppresses type 1 diabetes progression: II. Immunologic analysis. Diabetes (2006) 0.84

Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes. Biol Blood Marrow Transplant (2013) 0.83

The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice. PLoS One (2012) 0.80

Effect of docosahexaenoic acid supplementation on inflammatory cytokine levels in infants at high genetic risk for type 1 diabetes. Pediatr Diabetes (2014) 0.79

Erythrocyte membrane docosapentaenoic acid levels are associated with islet autoimmunity: the Diabetes Autoimmunity Study in the Young. Diabetologia (2013) 0.79

Fas stimulation results in selective islet infiltrate apoptosis in situ and reversal of diabetes. Ann N Y Acad Sci (2002) 0.78

Anti-lymphocyte antibody-based immunotherapy in type 1 diabetes. Chin Med J (Engl) (2013) 0.75

Indomethacin, dexamethasone, and intestinal damage in infant rats. J Pediatr Gastroenterol Nutr (2002) 0.75